In an effort to provide a guide for clinicians and a framework for future educational efforts, an international panel of healthcare stakeholders convened to arrive at consensus recommendations for the use of biosimilars to treat rheumatological diseases.
In an effort to provide a guide for clinicians and a framework for future educational efforts, an international panel of healthcare stakeholders convened to arrive at consensus recommendations for the use of biosimilars to treat rheumatological diseases. The resulting recommendations were published in Annals of the Rheumatic Diseases.
The multidisciplinary task force—25 experts from Europe, Japan, and the United States (17 rheumatologists, 1 rheumatologist/regulator, 1 dermatologist, 1 gastroenterologist, 2 pharmacologists, 2 patients with rheumatic diseases, and 1 research fellow—convened in 2016 to develop an evidence-based, consensus-based statement on biosimilars after appraising evidence in the scientific literature. The task force members deliberated and revised statements on overarching principles and recommendations, which were later voted on and accepted if an 80% consensus was met.
The group agreed on 5 overarching principles:
The group also arrived at 8 consensus recommendations:
The group concluded that the rapidly growing body of evidence has begun to reduce uncertainty about the use of biosimilars in treating rheumatic diseases. However, a treating physician should be the only one to decide whether to prescribe a biosimilar in place of a reference product, on a case-by-case basis, with the full awareness of the patient. While there is sufficient evidence about the safety and efficacy of biosimilars to allow for extrapolation of indications, there are not yet enough data to allay all concerns about switching among biosimilars or switching repeatedly between the reference and a biosimilar. To facilitate informed decision-making, providers are encouraged to gather pharmacovigilance data about the outcome of such switches.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.